BiotechTube
CapnoPharm

CapnoPharm

Hamburg, Germany· Est.
capnopharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

CapnoPharm is a private, clinical-stage biotech pioneering targeted aerosol delivery for peritoneal and pleural cancers. Built on the proprietary PIPAC platform, the company is advancing lead assets CapnoDC® and CapnoXal® towards regulatory approval, combining CE-marked nebulizers with reformulated chemotherapies. With strong IP, over €28M in raised R&D funding, and recent recognition from the European Commission, CapnoPharm is positioning itself as a leader in a niche but high-need oncology segment. The company operates as a partner for pharmaceutical firms seeking to enhance existing or next-generation drugs through its specialized delivery system.

Oncology

Technology Platform

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) platform, a drug-device combination system for locoregional delivery of therapeutic aerosols (chemotherapies, siRNA, mRNA, nanomolecules, viruses, immunotherapeutics) into peritoneal and pleural cavities.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The significant unmet need in treating peritoneal and pleural carcinomatosis creates a clear market for a targeted, effective therapy.
The platform's ability to partner with pharma companies to reformulate a wide array of drugs (from chemotherapies to immunotherapies) provides multiple revenue streams and reduces dependency on a single asset.

Risk Factors

Clinical and regulatory success for the lead drug-device combinations is not guaranteed.
Market adoption may be slow due to the novelty of the procedure and need for surgical training.
Competition could emerge from other companies developing similar locoregional delivery technologies.

Competitive Landscape

CapnoPharm is a pioneer in formalizing PIPAC as a regulated drug-device combination product. Direct competitors are limited but may include other medical device companies developing intraperitoneal delivery systems. Indirect competition comes from standard systemic therapies, other locoregional approaches like HIPEC (Hyperthermic Intraperitoneal Chemotherapy), and pharmaceutical companies developing new systemic agents for late-line cancer.

More companies in Drug Delivery & Formulation →More companies in Germany →